Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
30 8월 2023 - 2:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2023
Commission File Number 000-50112
RepliCel Life Sciences Inc.
(Translation of registrant’s name into English)
Suite 900 – 570 Granville Street, Vancouver, British Columbia V6C 3P1
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual
report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that
the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country
exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event,
has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
SUBMITTED HEREWITH
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RepliCel Life Sciences Inc.
/s/ Andrew Schutte
Andrew Schutte, President
Date: August 29, 2023
REPLICEL LIFE SCIENCES INC.
Suite 900 – 570 Granville Street
Vancouver, BC V6C 3P1
Telephone: (604) 248-8730 Fax: (604) 248-8690
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
VANCOUVER, BC –
August 16, 2023 - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2), (“RepliCel” or the “Company”), a company developing
next-generation technologies in aesthetics and orthopedics, announces the transition of a new Chief Financial Officer.
With great sorrow, RepliCel announces the passing of Simon Ma, our long tenured Chief Financial Officer. “Simon Ma
has been a valuable member of the team for many years, Simon’s deep commitment to the Company was always evident. We spent many late nights engaged on projects together. Simon’s commitment was unwavering, and he left an enduring impact on our team
and his legacy of integrity and leadership will continue to inspire us.” President & CEO Andrew Schutte stated.
David Kwok steps into the Chief Financial Officer role with a clear financial vision for the Company’s success. His
extensive expertise, honed while working with numerous public companies, positions RepliCel for the future. “David Kwok’s experience and expertise position him well to assume the role of Chief Financial Officer, David’s experience with public
companies for over 15 years will prove invaluable.” Andrew Schutte stated. David Kwok has been a Certified Professional Accountant for over 15 years and is a member of the Certified Professional Accountant of British Columbia since January 2008.
In connection with the appointment of David Kwok, the
Company has granted 150,000 stock options (each, an “Option”) to Mr. Kwok for the purchase of up to 150,000 common shares of the Company
pursuant to its 10% Rolling Stock Option Plan. Each Option is exercisable until August 16, 2027 at a price of $0.15 per common share and vest upon the date of grant.
In light of Simon Ma’s sudden passing, RepliCel will apply for a Management Cease Trade Order (MCTO) as the Company
completes a transition process and endeavours to file its second quarter financials in a timely manner.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what
the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of
healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles.
The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair
restoration. RCH-01 has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical study evaluating efficacy for the treatment of male and female hair loss due to androgenetic alopecia. This
ongoing study is being funded by Shiseido Company Limited pursuant to a license agreement which has now been terminated but is the subject of an arbitration regarding Shiseido’s rights to the product for Asia. RepliCel maintains the undisputed
rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel maintains the rights to
these products outside of Greater China.
RepliCel has also developed a proprietary injection device (DermaPreciseTM) and related consumables, which is expected to
improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the DermaPrecise™ device and consumables in Greater China for dermatology applications and is expected
to first launch the product in Hong Kong upon it being approved for market launch in either the United States or Europe. MainPointe Pharmaceuticals has an exclusive distribution agreement for the DermaPrecise™ device and consumables in the United
States, subject to income. MainPointe is expected to fund the FDA approval process in the United States. Please visit replicel.com for additional
information.
|
•
|
RepliCel’s three cell therapy products have now been tested in over 100 patients in four countries on three continents.
|
|
•
|
RepliCel now has key strategic regional partners each of which are now investing heavily in the further clinical testing and
development of RepliCel’s products for their markets. Data from each of the clinical programs will strengthen the product development initiatives for RepliCel and its other partners worldwide.
|
Please visit www.replicel.com for additional information.
For more information, please contact:
Andrew Schutte, CEO and President
info@replicel.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
51-102F3
MATERIAL CHANGE REPORT
Item 1 Name and Address of Company
RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
900 – 570 Granville Street
Vancouver, BC, V6C 3P1
Item 2 Date of Material Change
August 16, 2023
Item 3 News Release
The news release dated August 16, 2023 was disseminated through Market News and Stockwatch.
Item 4 Summary of Material Change
The Company announced the passing
of Simon Ma, the Company’s long tenured Chief Financial Officer.
David Kwok steps into the Chief Financial Officer role with a clear financial vision for the Company’s success. His
extensive expertise, honed while working with numerous public companies, positions RepliCel for the future. David Kwok has been a Certified Professional Accountant for over 15 years and is a member of the Certified Professional Accountant of British
Columbia since January 2008.
In connection with the appointment of David Kwok, the Company has granted 150,000 stock options (each, an “Option”) to Mr. Kwok for the purchase of up to 150,000 common shares of the Company pursuant to its 10% Rolling Stock Option Plan. Each Option is
exercisable until August 16, 2027 at a price of $0.15 per common share and vest upon the date of grant.
In light of Simon Ma’s sudden passing, the Company will apply for a Management Cease Trade Order (MCTO) as the Company
completes a transition process and endeavours to file its second quarter financials in a timely manner.
Item 5 Full Description of Material Change.
5.1 Full Description of Material Change
A full description of the material change is described in Item 4 above and in the News Release which has been filed on
SEDAR at www.sedar.com.
5.2 Disclosure for Restructuring Transactions
N/A
Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
N/A
Item 7 Omitted Information
None
Item 8 Executive Officer
Contact: Andrew
Schutte, CEO and President
Telephone: 604.248.8693
Item 9 Date of Report
August 18, 2023
RepliCel Life Sciences (CE) (USOTC:REPCF)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
RepliCel Life Sciences (CE) (USOTC:REPCF)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
